This retrospective cohort study found GLP-1 RAs were more effective than SGLT2 inhibitors in reducing the 3-year risk of composite cardiovascular events, especially SHF progression and stroke in patients with HFpEF and DM. This evidence concerns the gene GLP1R and diabetes mellitus.